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Introduction
1INTRODUCTION
                HIV infection/AIDS has become a major public health problem in
India. Although the median interval between HIV-1 infection and the
development of the Acquired Immune Deficiency Syndrome in adults is 10 to
11 years, some infected persons rapidly progress to AIDS in less than five
years. The biological basis of this variability is unknown but differences in viral
strains, host immune response and exposure to microbial or environmental
factors probably contribute. Identification of laboratory tests that help predict
the progression  to AIDS in people infected with HIV is desirable because of its
implication for both clinical management and prognosis.
                Quantitative measurement of HIV RNA levels in peripheral blood has
contributed significantly to the understanding of the pathogenesis of HIV
infection and has been shown to be an essential parameter in the prognosis and
optimal management of HIV infected individuals . CD4+ T cell count is the
laboratory test generally accepted as the best indicator of the immediate state of
immunologic competence of the patient with HIV infection.It has been shown to
correlate very well with the level of immunologic competence of the patient.
            In view of above, this study was taken to determine the clinical profile,
immunological and virological status of the HIV seropositive patients.
Review of
Literature
2EPIDEMIOLOGY
             HIV infection/AIDS is a global pandemic with cases reported from
virtually every country. At the end of 2007, 33.2 million individuals were living
with HIV infection (range: 30.6–36.1 million) according to the Joint United
Nations Programme on HIV/AIDS (UNAIDS).1 More than 95% of people living
with HIV/AIDS reside in low and middle income countries. 50% are females
and 2.5 million are children less than 15 years.
           In Asia, an estimated 4.9 million people were living with HIV infection
at the end of 2007.1 National HIV prevalence is highest in South East Asia with
wide variation in trends between different countries. The epidemic in Asia
lagged temporally behind that in Africa. However, the population of many
Asian nations are so large (especially India and China) that even low national
HIV prevalence rates result in large numbers of people living with HIV
infection.
        The HIV epidemic in India is concentrated in nature. The HIV prevalence
among the High Risk Groups i.e. Female Sex Workers, Injecting Drug Users,
Men who have Sex with Men and Transgenders is higher than the general
population. In 2009 it was estimated that approximately 2.39 million people
were infected with HIV in India, of which  39% were females and 4.4% were
3children. The four high prevalence states of South India(Tamil Nadu, Kerala,
Karnataka,Andhra Pradesh) account for 55% of these cases. Unprotected sex
(87.4% heterosexual and 1.3% homosexual) is the major route of HIV
transmission, followed by transmission from Parent to Child which is 5.4% and
the use of infected blood and blood products which is 1.0%. While Injecting
Drug Use is the predominant route of transmission in Northeastern states, it
accounts for 1.7% of HIV infections nationally. 2
HIV STRUCTURE AND GENOME
          HIV is different in structure from other retroviruses. It is around 120 nm
in diameter and  spherical.HIV-1 is composed of two copies of single-stranded
RNA enclosed by a conical capsid comprising the viral protein p24, typical of
lentiviruses . The RNA component is 9749 nucleotides long.3 The single-
stranded  RNA is tightly bound to the nucleocapsid proteins, p6, p7 and
enzymes that are indispensable for the development of the virion, such as
reverse transcriptase and integrase. The nucleocapsid (p7 and p6) associates
with the genomic RNA (one molecule per hexamer) and protects the RNA from
digestion by nucleases. A matrix composed of an association of the viral protein
p17 surrounds the capsid, ensuring the integrity of the virion particle. Also
enclosed within the virion particle are Vif, Vpr, Nef, p7 and viral Protease . The
4envelope is formed when the capsid buds from the host cell, taking some of the
host-cell membrane with it. The envelope includes the glycoproteins gp120 and
gp41.
             HIV has several major genes coding for structural proteins that are
found in all retroviruses  and several nonstructural ("accessory") genes that are
unique to HIV. The gag gene provides the basic physical infrastructure of the
virus, pol gene provides the basic mechanism by which retroviruses reproduce,
while the others help HIV to enter the host cell and enhance its reproduction.
Though they may be altered by mutation, all of these genes except tev exist in
all known variants of HIV.
? gag (group-specific antigen): codes for the Gag polyprotein, which is
processed during maturation to MA (matrix protein  p17); CA (capsid
protein  p24); SP1 (spacer peptide 1  p2); NC (nucleocapsid protein  p7);
SP2 (spacer peptide 2  p1) and p6.
? pol: codes for viral enzymes reverse transcriptase, integrase, and HIV
protease.
? env (for "envelope"): codes for gp160 - the precursor to gp120 and gp41
which are proteins embedded in the viral envelope.  This  enables  the
virus to attach to and fuse with target cells.
? Transactivators: tat, rev, vpr
5? Other regulators: vif, nef, vpu
? tev:  This  gene  is  only  present  in  a  few  HIV-1  isolates.  It  is  a  fusion  of
parts of the tat, env, and rev genes, and codes for a protein with some of
the properties of tat, but little or none of the properties of rev.4
PATHOPHYSIOLOGY AND PATHOGENESIS
                The hallmark of HIV disease is a profound immunodeficiency
resulting primarily from a progressive quantitative and qualitative deficiency of
the subset of T lymphocytes referred to as helper T cells. This subset of T cells
is  defined  phenotypically  by  the  presence  of  the  CD4  molecule  on  its  surface
which serves as the primary cellular receptor for HIV. A co-receptor must also
be  present  together  with  CD4  for  efficient  fusion  and  entry  of  HIV-1  into  its
target cells. HIV uses two major co-receptors for fusion and entry; these co-
receptors are also the primary receptors for certain chemoattractive cytokines
termed chemokines and belong to the seven-transmembrane-domain G protein–
coupled family of receptors. CCR5 and CXCR4 are the major co-receptors used
by HIV. A number of mechanisms responsible for cellular depletion and/or
immune dysfunction of CD4+ T cells have been demonstrated in vitro; these
include direct infection and destruction of these cells by HIV and immune
clearance of infected cells, as well as indirect effects such as immune
exhaustion due to aberrant cellular activation and activation-induced cell
6death.1There are various stages in the lifecycle of HIV. This includes the
following.
Binding and fusion:
HIV uses the CD4 molecule on the surface of the T lymphocyte as a primary
receptor. Viral gp120 binds the CD4 molecule on the surface of the T
lymphocyte leading to conformational change exposing the binding site for co-
receptors (chemokine receptors) present on the surface of the T lymphocytes.
The viral envelope fuses with the host cell membrane leading to the release of
viral RNA copies in the protoplasm of the host cell.5
Reverse transcription:
Viral reverse transcriptase transcribes the single stranded HIV RNA to double
stranded DNA that moves to the nucleus.6
Integration:
The enzyme integrase integrates the HIV DNA to host DNA. Integrated HIV
DNA is called as provirus. The provirus may remain inactive for several years
producing few or no copies of HIV. 7
7Transcription:
When host cell is activated, the provirus integrated in the host genome is also
transcribed by host’s RNA polymerase to create copies of HIV genomic
material and also m RNA which produces the HIV proteins.
Assembly:
HIV protease cuts long chains of HIV protein into smaller individual proteins.
HIV proteins with the genetic material form the new virus particles.8
Budding:
The newly assembled virus buds from the host cell. During budding , HIV
envelope acquires host membrane protein and lipid bilayer.
8NATURAL HISTORY OF HIV INFECTION
Acute stage of HIV infection (window period):
From the time of infection it may take 3-6 weeks for anti HIV antibodies to
develop. This is called as the window period. There is a surge of plasma viremia
with plasma viral load reaching peak in 2-3 weeks and loss of helper T cells in
this period. The host generates immune response that helps in controlling the
virus replication leading to sharp decline in plasma viremia. The patient
presents with fever, arthralgia, myalgia, headache, rashes. This is self limiting.
About 9-12 months post infection a steady state plasma viremia is reached (viral
set point). This set point is prognostic.
Clinically latent phase of HIV infection:
The plasma viral load remains stable for several years post plasma viral load set
point. Though viral load does not increase, there is constant multiplication of
virus leading to destruction of CD4 lymphocytes. Based on the speed of disease
progression HIV -1 infected individuals can be categorized as typical
progressors, rapid progressors and long time non progressors. Typical
progressors show a latent period of 5 -8 years before appearance of clinical
AIDS.  About  10%  of  the  HIV  infected  rapidly  progress  to  AIDS  within  2-3
years of infection called as rapid progressors. 5% do not show clinical
9symptoms even after 10 years of infection in the absence of ART called as long
time non progressors.
AIDS stage:
In this stage, there is a rapid decline in CD4 count (<200cells) and patient
acquires opportunistic infections and malignancies.9
LONG TERM NON PROGRESSORS:
Individuals infected with HIV for a long period ( 10 years or more), whose CD4
T cell counts are normal and have remained stable over years and who have not
received  antiretroviral therapy are regarded as long term non progressors.
These patients have a low viral burden, normal immune function and normal
lymphoid architecture. Other factors associated with this state include a
defective virus that is of low virulence, defective nef gene and defective
chemokine receptors.10
VIRAL DYNAMICS
The half-life of a circulating virion is approximately 30 to 60 min and that of
productively infected cells is 1 day. Given the relatively steady level of plasma
viremia and of infected cells, it appears that extremely large amounts of virus
(1010 to 1011 virions) are produced and cleared from the circulation each day. In
10
addition, data suggest that the minimum duration of the HIV- 1 replication cycle
in vivo is 2 days. Other studies have demonstrated that the decrease in plasma
viremia that results from antiretroviral therapy correlates closely with a decrease
in virus replication in lymph nodes, further confirming that lymphoid tissue is
the main site of HIV replication and the main source of plasma viremia. The
level of steady-state viremia, called the viral set point, at 1year has important
prognostic implications for the progression of HIV disease. It has been
demonstrated that HIV-infected individuals who have a low set point at 6
months to 1 year progress to AIDS much more slowly than individuals whose
set point is very high at that time. Levels of viremia generally increase as the
disease progresses. Measurement of the level of viremia is critical in guiding
therapeutic decisions in HIV-infected individuals.11
CELLULAR TARGETS OF HIV
Although the CD4+ T lymphocytes and CD4+ cells of monocyte lineage are the
principal targets of HIV, virtually any cell that expresses the CD4 molecule
together with co-receptor molecules can potentially be infected with HIV.
Circulating dendritic cells have been reported to express low levels of CD4 and
depending on their stage of maturation, these cells can be infected with HIV.
Epidermal Langerhans cells express CD4 and have been infected by HIV in
vivo.  HIV has been reported also to infect a wide range of cells and cell lines
11
that express low levels of CD4, no detectable CD4, or only CD4 mRNA.
Among these are Functional dendritic cells, megakaryocytes, eosinophils,
astrocytes, oligodendrocytes, microglial cells, CD8+ T cells, B cells, and NK
cells as well as a variety of organ-specific cells.12
MECHANISMS OF CD4 T LYMPHOCYTE
DESTRUCTION
? Direct or single cell killing : Infected  CD4 cells may be killed directly
when large number of virus is produced and bud off from the cell surface,
disrupting the cell membrane, or when viral protein and nucleic acids
collect inside the cell, interfering with cellular machinery.13
? Syncytia formation : Infected cells may fuse with nearby uninfected
cells  forming balloon like giant cells called syncytia.14
? Apoptosis : Infected CD4 cells may be killed when cellular regulation is
altered by HIV proteins, probably leading to their suicide process known
as apoptosis.15
? Innocent Bystanders: HIV particles may bind to the cell surface, making
them appear as infected cells and marking them for destruction by killer T
cells.
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? Anergy: A negative signal is delivered to CD4 T cells after their
component CD4 molecules react with gp120 or gp120-antigp120
complexes.16
? Super antigens: Viral protein nef is a super antigen, which activates the
CD4 T cells for viral replication.17
? Damage to precursor cells: Studies suggest that HIV destroys precursor
cells that mature to have special immune functions, as well as parts of the
bone marrow and thymus needed for the development of such cells.
ROUTES OF HIV TRANSMISSION
Blood transfusion: 90-95%
Perinatal transmission: 20-40%
Sexual intercourse: 0.1- 10%
Vaginal intercourse: 0.05- 0.1%
Anal intercourse: 0.065 -0.5%
Oral sex: 0.005-0.01%
Injection drug abuse: 0.67%
Needle stick exposure : 0.3%
13
WHO STAGING
WHO clinical staging of HIV /AIDS of adults and adolescents (2006)
 Clinical stage 1
? Asymptomatic
? Persistent generalized lymphadenopathy
Clinical stage 2
? Unexplained moderate weight loss (<10% of presumed or measured body
weight)
? Recurrent respiratory tract infections (sinusitis, tonsillitis, otitis media,
pharyngitis)
? Herpes zoster
? Angular cheilitis
? Recurrent oral ulceration
? Papular pruritic eruptions
? Seborrhoeic dermatitis
? Fungal nail infections
Clinical stage 3
? Unexplained severe weight loss (>10% of presumed or measured body
weight)
? Unexplained chronic diarrhoea for longer than one month
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? Unexplained persistent fever (above 37.5degree Celsius ,intermittent or
constant for longer than one month)
? Persistent oral candidiasis
? Oral hairy leukoplakia
? Pulmonary tuberculosis
? Severe bacterial infections (e.g. pneumonia, empyema, pyomyositis, bone
or joint infection, meningitis, bacteremia)
? Acute necrotizing ulcerative stomatitis, gingivitis or periodontitis
?  Unexplained anaemia (<8 g/dl), neutropenia (<0.5 X 109/litre) and /or
chronic thrombocytopenia(<50 X 109/litre)
Clinical stage 4
? HIV wasting syndrome
? Pneumocystis pneumonia
? Recurrent severe bacterial pneumonia
? Chronic herpes simplex infection (orolabial, genital or anorectal of more
than one month’s duration or visceral at any site)
? Oesophageal candidiasis (or candidiasis of trachea, bronchi or lungs)
? Extrapulmonary tuberculosis
? Kaposi’s sarcoma
? Cytomegalovirus infection (retinitis or infection of other organs)
? Central nervous system toxoplasmosis
15
? HIV encephalopathy
? Extrapulmonary cryptococcosis including meningitis
? Disseminated non-tuberculous mycobacterial  infection
? Progressive multifocal leukoencephalopathy
? Chronic cryptosporidiosis
? Chronic isosporiasis
? Disseminated mycosis (extrapulmonary histoplasmosis,
coccidiodomycosis)
? Recurrent septicaemia (including non-typhoidal salmonella)
? Lymphoma (cerebral or B cell non-Hodgkin)
? Invasive cervical carcinoma
? Atypical disseminated leishmaniasis
? Symptomatic HIV-associated nephropathy or symptomatic HIV-
associated cardiomyopathy
1. Assessment of body weight in pregnant woman needs to consider expected
weight gain of pregnancy.
2. Unexplained refers to where the condition is not explained by other
conditions.
3. Some additional specific conditions can also be included in regional
classifications (e.g. reactivation of American trypanosomiasis
16
meningoencephalitis and/or myocarditis in Americas region, Penicilliosis in
Asia).18
DERMATOLOGICAL MANIFESTATIONS OF
HIV INFECTION
The cutaneous manifestations of HIV infection according to the CD4 count is as
follows:
CD4 count Dermatological manifestations
 500 -1000 HIV exanthems in seroconversion illness, Tinea corporis,
Psoriasis, Seborrheic dermatitis, Bullous impetigo.
200-500 Bacterial folliculitis, Pityriasis versicolor,Warts,
Molluscum contagiosum, Herpes zoster.
 < 200 Herpes simplex, Acquired icthyosis, Papular follicular
eruptions, Oral candidiasis, Oral hairy leukoplakia,
Kaposi’s sarcoma, Norwegian scabies, Cryptococcosis,
Penicilliosis, Tuberculosis.19,20
17
MARKERS OF DISEASE PROGRESSION
Viral load:
Plasma HIV RNA load is considered the most representative and sensitive
laboratory test for monitoring progression of HIV infection and response to
antiretroviral therapy.21,22,23 Active replication occurs in all the stages. Viral load
ranges between 102 and 107 copies /ml in untreated cases and is lower in those
on  treatment.  Techniques  available  are  RNA  PCR,  b  DNA  assay  (branched
chain DNA assay), NASBA (Nucleic acid sequence based amplification). RNA
PCR detects  40  copies/  milliliter  and  is  positive  in  >  98% of  patients.  b  DNA
assay detects 500 copies/ milliliter and is positive in >90% of the patients.
While p24 antigen reflects changes in viral burden over an extended period,
viral load measurement reflects the changes in HIV RNA levels over a few
hours. Viral load levels are about ten fold lower in long time non progressors
than in patients with progressive disease. Persistently detectable viremia and
high baseline levels indicate poor prognosis. Risk of progression is low at
copies less than 10,000 /ml. High viral load correlates with low baseline CD4
count, faster decline in CD4 count and faster disease progression.24,25,26
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Interim recommendations for viral load assays:
Plasma HIV RNA levels that suggests initiation of treatment:
More than 5000-10,000 copies/ml and a CD4 count or clinical status suggestive
of progressive disease.
Target level of HIV RNA level after initiation of treatment:
Undetectable : <5000 copies /ml is an acceptable target.
Minimal decrease in HIV RNA indicative of antiviral activity:
>0.5 log decrease.
Change in HIV RNA that suggests drug treatment failure:
Return to (or  within 0.3 to 0.5 log of)  pretreatment value,  or  a  significant  rise
(0.7- 1.0 log) from the treatment nadir.
Suggested frequency of HIV RNA measurements:
At baseline, 2 measurements 2-4 weeks apart. Then every 3-4 months or in
conjunction with CD4 count. 4-8 weeks after initiating or changing therapy.27
19
Serum p24 antigen:
HIV antigen detection tests use EIA technology for detection of HIV antigen in
serum, plasma, urine. This can also detect p24 antigen in blood of HIV infected
patients ,where it exists as free antigen or complexed to anti p24
antibody.28,29,30,31 The sensitivity increases when the samples are treated with a
weak acid to dissociate antigen antibody complexes prior to assay. Serum
immune complex dissociated antigenemia was also associated with AIDS
development. This is a less sensitive marker than plasma HIV RNA levels.
During first few weeks of infection there is a brisk rise in p24 antigen level.
After development of anti p24 antibody these antigen levels decline. Later in the
course of the disease, when circulating levels of free virus are high, p24 antigen
levels also increase.32 Sensitivity  of  the  test  is  4%  in  asymptomatic  ,  56%  in
AIDS related complications, 70% in AIDS.33 It has been shown that for a group
of asymptomatic HIV infected patients with similar CD4 counts, those with a
detectable level of p24 antigen are 3 times more likely on an average to show
progression to AIDS than those in whom p 24 antigen levels cannot be detected.
In patients on ART, there is a decline in circulating levels of p24 anigen. But it
has a limited role in diagnosis and is not considered a useful prognostic
marker.21
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Serum p24 antibody:
Antibody to HIV p24 antigen begin to appear within several weeks of acute
HIV infection. The level of p24 antibody declines because of formation of
circulating immune complexes with p24 antigen. Thus a drop in titre of p24
antibody predicts an increase in viral load and increased risk of progression to
AIDS.34
Assays for qualitative viral change:
Syncytium inducing strains:
Some HIV strains form syncytia or giant cells in certain continous cell culture
lines. Syncytium inducing strains are more likely than non syncytium inducing
strains to be seen at the end stage of infection, associated with increased viral
load, a blunted CD4 response to ART, more rapid decline in CD4 count,drug
resistance and progressive clinical deterioration. This assay is expensive and not
routinely used.35,36
CD 4 cell count:
CD4 is one of the several glycoproteins termed as “cluster of differentiation
antigens” expressed on the surface of lymphocytes . CD4 count can be
measured by flow cytometry, microsphere assay and enzyme immunoassay.
CD4 serves as a receptor for HIV and cells expressing this protein usually
21
decline in number with progressive HIV infection. Its decline is the hallmark of
HIV infection. CD4 cell count is extremely important in staging of HIV
infection and a revised classification of the centre for disease control divide
HIV positive patients into 3 CD4 count categories. > 500/ microlitre, 200-499/
microlitre,< 200/microlitre. A low CD4 count (<10%), number < 100/microlitre,
and a CD4 /CD8 ratio (<0.2) are highly predictive for death from AIDS related
complications.37,38
Percentage of CD4 cells:
The total  number  of  CD4 cells  in  any  one  sample  are  influenced  by  specimen
handling , age of the patients , time of sampling( low count in the morning), use
of pharmacological agents and presence of infection. So more value is given to
percentage of CD4 cells as a marker of immune function and progression to
AIDS. Normally CD4 count of 200/microlitre is equivalent to 20% of
lymphocyte count. The normal range of CD4 count is 500- 1300/ microlitre and
percentage is 38-65%. When CD4 count varies unexpectedly or clinical stage
does not correlate with CD4 count, then CD 4 percentage and its variation over
time should be monitored.39
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CD8 cell count:
It is not as useful as CD4 count as it remains elevated for many years after
infection. However in advanced immunodeficiency ( CD4 < 200), a marked
decline in CD8 levels indicate poor prognosis.22,34
Multitest delayed type hypersensitivity skin test:
Semiquantitative measurement of immune function. Lack of response ( anergy )
is associated with a poor prognosis. Testing involves placement of a panel of 7
purified recall antigens on the volar aspect of the forearm with the diameter of
induration of each reaction measured 48 hours later. Reactions > 2mm diameter
is considered as positive. Failure to respond to any antigen is considered as
anergy and indicates poor cell mediated immunity. The use of gp160 in a
delayed type hypersensitivity test panel is being investigated.22,34
Soluble markers:
Neopterin:
Neopterin is a low molecular weight protein derived from an intermediate
product of denovo biosynthesis of tetrahydrobiopterin from guanosine
triphosphate. Its produced by activation of monocytes and B cells. It is an early
marker of HIV infection.21,23,34,40 Its levels further rise on progression from pre
AIDS to clinical AIDS.  It is a non specific marker as it is also positive in viral
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infections, advanced malignancies, collagen vascular disorders, atypical
phenylketonuria, patients on immunostimulants. Neopterin assay can be done
by ELISA or RIA .Serum or urine levels of neopterin are higher in patients with
advanced HIV infection and in asymptomatic patients higher levels are
associated with increased progression to AIDS that is independent of CD4
count.41,42,43 In the San Francisco cohort study, patients with neopterin levels
< 12nmol/l, 12-17nmol/l, >17nmol/l had 3 years rate of progression to AIDS of
10%, 20%, 45% respectively.39
Beta 2 microglobulin:
It is a 11kDa protein that is expressed on the surface of most nucleated cells. It
forms a heterodimer with class 1 MHC molecules present on the surface of most
nucleated cells. It also exhibits aminoacid homology with the constant region of
immunoglobulin. Free beta 2 microglobulin can be measured in the serum and
urine and correlates with the progression of HIV infection. Levels of  beta 2
microglobulin are increased in conditions characterized by lymphocyte
activation or destruction such as lymphoproliferative syndromes, autoimmune
diseases, viral infections, renal diseases, hemophiliacs, drug abusers. It can be
measured  by  RIA  or  ELISA.44 Increased beta 2 microglobulin levels are
associated with decreased CD4 cell counts. In the Sanfrancisco cohort study,
beta 2 microglobulin levels <3 mg/l, 3-5mg/l, > 5mg/l had 3 years of
progression to AIDS  of 12%, 33%, and 69% respectively.45,46,47
24
Other markers:
Serum IgA levels48
Serum cytokine levels (TNF ? and IFN )23,34
Soluble IL- 2 receptor levels.49
DIAGNOSIS
HIV infection can be detected in the laboratory either by detection of antibodies
to HIV or by detection of virus, its antigen and its DNA or RNA.
Antibody detection:
Screening tests:
ELISA (Enzyme linked immunosorbent assay)
It is the most commonly performed test.
The types of ELISA based on the principle are indirect ELISA, competitive
ELISA, sandwich ELISA, Immunocapture ELISA.
ELISA can also be classified based on the antigen utilized into first generation,
second generation ,third generation, fourth generation.
First generation – infected cell lysates is used as antigen.
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Second generation – glycopeptides is used as antigen.
Third generation – synthetic peptides are used as antigen.
Fourth generation – antigen and antibody are detected simultaneously.
Rapid tests:
This includes the following tests:
1. Dot blot assays (Immunoconcentration based)
2. Particle agglutination ( Gelatin, RBC, latex, microbeads)
3. Dipstick and COMB tests ( ELISA technology based)
4. Immunochromatography based tests ( lateral flow of reagents)
Supplemental tests:
These are the following.
1. Second and third generation ELISA / rapid tests.
2. Western blot.
Detection of p24 antigen:
This is done in the following conditions:
1. To detect infection in the newborns
2. To resolve equivocal Western blot results.
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3. To detect infection during early window period.
4. To diagnose CNS Infection.
5. Late stages of the disease.
6. For research purposes.
7. To monitor response to antiretroviral therapy.
Viral culture:
It is another method for identifying HIV infection. But it is expensive and
labour intensive. It is mainly used for research purposes.
STRATEGIES OF HIV TESTING
The various strategies designed involve the use of various categories of tests in
various permutations and combinations.
1. Screening tests – ELISA/ rapid tests (E/R).
2. Supplemental tests E/R and Western blot.
Western blot is used where discordant serological results are obtained. If
Western blot is not available, then client should be retested again after 2-4
weeks.
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Strategy 1:
Blood/serum/plasma is subjected once to E/R for HIV. If negative, the sample is
considered free of HIV and if positive, the sample is taken as HIV infected for
all practical purposes. This strategy is used for ensuring donation safety (blood,
organs, tissues, sperms ).
Strategy 2 A:
A serum sample is considered negative for HIV if the first ELISA or rapid test
is negative , but if reactive the same sample is subjected to a second ELISA or
rapid test which utilises a different system from the first one , that is either the
principle of the test /and/or the antigen used is different. It is reported reactive
only if the second ELISA / rapid test confirms the positive report of the first
test. In case the second E/R is nonreactive, then the test result is taken as
negative for surveillance purposes. This strategy is used for sentinel
surveillance.
Strategy 2 B:
This strategy is used for detection of HIV infection in symptomatic individuals
with symptoms of AIDS clinically. A sample reactive with the first assay and
nonreactive with the second assay is subjected to the third test E/R. If the third
test E/R is reactive , the sample is reported as indeterminate and the patient is
called for repeat testing after 2-4 weeks. If the third test is negative, it is
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reported as negative. In this strategy if the first 2 consecutive tests are positive,
a positive report can be given to the patient.
Strategy 3:
Testing is  done as in strategy 2 B.   However added confirmation of  a  3rd  E/R
reactive test is required for  a sample to be reported as HIV positive .If the
sample gives reactive result with 2 E/R and nonreactive with the third assay, it
is reported as indeterminate and the patient is called back for repeat testing after
2- 4 weeks . The test used as the screening test is of high sensitivity and the
supplemental test is of high specificity. This strategy is used for diagnosis of
HIV infection in asymptomatic individuals.50
LABORATORY DIAGNOSTIC METHODS
RETROCHECK:
 It is a third generation , rapid, qualitative, two side sandwich immunoassay for
the simultaneous detection of antibodies specific to the HIV 1 and HIV 2 virus
in  serum,  plasma  or  whole  blood.  The  test  employs  recombinant  proteins
representing the highly immune dominant envelope and core regions of HIV 1
(gp41 and p24-0- subtype fusion polypeptide) and the envelope region of HIV 2
(gp36).  The principle used is lateral flow immunochromatography, a 2 site
double antigen sandwich immunoassay on a membrane. As the test specimen
flows through the membrane of the test assembly, the coloured HIV specific
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recombinant antigen- colloidal gold conjugate complexes with HIV antigen in
the sample. This complex moves  further on the membrane of the test region ‘T’
where it is immobilized by the HIV specific recombinant antigen coated on the
membrane leading to the formation of a coloured band which confirms a
positive test result. Absence of the coloured band in the test region ‘T’ indicates
a negative test result. The unreacted conjugate and unbound complex if any,
move further on the membrane and are subsequently immobilized by the
antirabbit antibodies coated on the membrane at the control region ‘C’ forming
a coloured band. This control band serves to validate the reagent and the test
performance.51
SD BIOLINE HIV ½ 3.0:
SD BIOLINE HIV ½ 3.0 test is an immunochromatographic test for the
qualitative detection of antibodies of all isotypes (IgG, IgM, IgA) specific to
HIV -1 and HIV -2 simultaneously in human serum , plasma or whole
blood.This test contains a membrane strip precoated with recombinant HIV -1
capture antigen( gp41,p24) on test band 1 region and recombinant HIV -2
capture antigen(gp36) on test band 2 region respectively. The recombinant HIV-
1/2 antigen (gp41,p24, gp36) – colloidal gold conjugate and the specimen
sample move along the membrane chromatographically to the test region (T)and
form a visible line as the antigen – antibody- antigen gold particle complex
forms with high degree of sensitivity and specificity.52
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COMBAIDS:
COMBAIDS - RS advantage is a dot immunoassay for the detection of
antibodies to HIV -1 and HIV -2 in the  whole blood , human serum, plasma.
This is an indirect solid phase enzyme immunoassay. The solid phase is a comb
with 12 projections. Each tooth has 3 spots. Upper spot: goat antibody to human
Ig. Middle spot : HIV-1 synthetic peptides. Lower spot : HIV-2 synthetic
peptides. The developing plate has 6 rows (12 wells each) with each row
containing  a  reagent  solution  ready  for  use  at  different  steps  in  the  assay.  Ig
solution present in the test samples as captured by the antihuman Ig antibody on
the upper spot (internal control). Unbound components are washed away. IgG
from the sample is captured on the teeth and reacts with antihuman IgG
antibody labelled with alkaline phosphatase which reacts with chromogenic
components and the results are seen as gray- blue spots on the surface of the
teeth of the comb.
Interpretation of controls:
Appearance of upper spot: negative control.
Appearence of all 3 spots: positive control.
Upper spot does not appear: invalid result.
Interpretation of results:
Appearance of upper spot:  nonreactive sample
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Appearance of upper and middle spot: reactive for HIV-1.
Appearance of upper and lower spot: reactive for HIV-2 .
Appearance of all the 3 spots: reactive for HIV-1 and HIV-2.53
CD4 COUNT DETERMINATION BY FLOW CYTOMETRY:
Flow cytometry refers to a technology that simultaneously measures and
analyses multiple physical and chemical characteristics of single cells or other
biological particles, as they flow in a fluid stream past optical and / or electronic
sensors. It provides information about their relative size , relative granularity or
internal structure and fluorescence in several spectral regions emitted by
fluorochrome labelled probes which bind specifically and stoichiometrically to
cellular constituents such as protein and nucleic acid. Individual cells stained
with fluorescent labels or absorption dyes are suspended in a physiological
solution and introduced under a slight pressure through a flow chamber into the
centre of a stream of cell free sheath fluid. The light scattered by the individual
particle and the fluorescence emitted by the cells is used for analysis and sorting
of the cells based on the fluorescence antibody directed against a specific
surface antigen. This combination of scattered and fluorescent light is picked up
by the detectors in the flow cytometer. These detectors then produce electronic
signals that are proportional to the optical signals received.
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The visible light undergoes deflection based on the size and the internal
structure of the cells. Forward scatter correlates with cell volume. Side scatter
depends on the shape of the nucleus,  amount and type of cytoplasmic granules.
The fluorescence  emitted by the cells depends on the flourescence tagged
specific monoclonal antibodies- antigen cell surface markers. The data collected
on each cell is stored in the computer. This data is then processed and analysed
to provide information about all cell populations within the sample.54,55
REAL TIME HIV-1 PCR ASSAY:
       The RealTime HIV-1 assay amplifies a fragment of 172 nucleotides from a
highly conserved region of the integrase gene. The assay incorporates an
internal control (IC) that is unrelated to the HIV-1 target sequence and the
hydroxypyruvate reductase gene from the pumpkin plant (Cucurbita pepo),
which is introduced into each specimen at the beginning of the sample
preparation. During each round of thermal cycling, amplification products
dissociate to single strands at a high temperature, allowing primer annealing and
extension as the temperature is lowered. Exponential amplification of the
product is achieved through repeated cycling between high and low
temperatures. Amplification of both targets, HIV-1 and IC, takes place
simultaneously in the same reaction. The hybridization of the HIV cDNA
molecules and IC-specific probes, labeled with a different fluorescent dye, using
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lower temperatures than primer annealing allows the best detection of different
HIV variants. The amplification cycle at which a fluorescent signal is detected
is proportional to the amount of HIV-RNA present in the original sample. The
lower limit of detection is defined as the HIV-RNA concentration detected with
a probability of 95% or greater; depending on the sample volume used for RNA
isolation. A lower limit of detection of 40 HIV-RNA copies/ml has been
established when RNA is isolated from 1 ml of plasma. 56
Aim of the Study and
Materials& Methods
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AIM
To determine the clinical,virological and immunological status of HIV positive
patients who attend Institute of Venereology and ART centre  at Madras
Medical College, Chennai.
MATERIALS AND METHODS
Study design: Cross sectional study
Study period: May 2010 - August 2011
Subject Selection: 50 treatment naive HIV positive patients diagnosed at
Institute of Venereology and ART Centre at Madras Medical College ,Chennai
were randomly selected for the study.
Inclusion Criteria:
? Patients who were positive for HIV infection.
? Patients who were at the various stages (WHO staging) of HIV disease.
Exclusion criteria
? HIV positive patients who were on ART.
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Study:
  Patients selected for study were subjected to detailed clinical
history,examination and necessary routine laboratory investigations. Clinical
staging was done according to the WHO clinical staging for AIDS.
       At  recruitment,  blood  samples  were  taken  from  all  the  patients  in  a  plain
vial for serum HIV testing and EDTA vacutainer for whole blood CD4 cell
count and plasma viral load determination after obtaining informed consent.
Laboratory methods:
? Serodiagnosis of HIV infection will done by
                               Test 1 –RETROCHECK
                               Test 2- SD BIOLINE HIV ½ 3.0
                               Test 3- COMBAIDS
Strategy used: Strategy 3
? Absolute CD4 lymphocyte count  determined by Flow cytometry
? Viral load  done using Real-Time PCR :
 Real-Time PCR based HIV Assay was standardized and done by
HELINI Biomolecules.
Observations
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RESULTS
VIROLOGICAL, IMMUNOLOGICAL AND
CLINICAL STATUS OF THE PATIENTS:
WHO stage Patient ID CD 4 count/µl HIV RNA copies/ml
1. Stage I
19 patients
P001 419 12388
2. P003 327 23129
3. P004 324 80252
4. P006 705 23346
5. P007 368 67816
6. P011 390 23002
7. P013 921 41344
8. P015 447 77231
9. P016 519 3463
10. P018 226 372033
11. P020 368 458492
12. P026 308 30034
13. P028 459 18990
14. P032 503 12542
15. P036 223 142971
16. P040 309 43671
17. P046 466 12899
18. P047 327 38862
19. P048 390 331241
20. Stage II
10 patients
P005 302 3359
21. P008 438 1973
22. P009 488 2200
23. P017 505 212
24. P022 356 3459
25. P031 412 1183
26. P038 342 1114
27. P041 220 7114
28. P045 492 3981
29. P049 356 2345
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WHO stage Patient ID CD 4 count/µl HIV RNA copies/ml
30. Stage III
18 patients
P002 55 8542
31. P010 131 31203
32. P012 68 9243
33. P014 447 2334
34. P019 386 1276
35. P021 211 29842
36. P023 443 1370
37. P025 364 16711
38. P024 268 1263
39. P027 339 3331
40. P029 333 4457
41. P033 301 11932
42. P034 254 100
43. P035 184 7112
44. P042 65 29022
45. P043 296 40021
46. P044 493 1459
47. P050 339 14921
48. Stage IV
3 patients
P030 38 197432
49. P037 92 49025
50. P039 53 131315
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DISTRIBUTION OF PATIENTS IN DIFFERENT
STAGES
WHO Staging No of patients Percentage
I 19 38%
II 10 20%
III 18 36%
IV 3 6%
? Maximum number of patients were in WHO stage I (38%).
? 36% of the patients were in WHO stage III.
?  20% of the patients were in WHO stage II.
?  Only 6% of the patients were in WHO stage IV.
DISTRIBUTION OF PATIENTS IN
DIFFERENT STAGES
38%
20%
36%
6%
Stage I Stage II Stage III Stage IV
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RANGES OF ABSOLUTE CD4 LYMPHOCYTES
PER µl IN HIV INFECTED INDIVIDUALS
CD 4 count
ranges in
cells /µl
WHO staging- no of patients Total no
of
patients
Percentage
Stage I Stage II Stage III Stage IV
>500 4 1 0 0 5 10%
350-500 8 6 5 0 19 38%
200-349 7 3 8 0 18 36%
50-199 0 0 5 2 7 14%
<50 0 0 0 1 1 2%
Mean CD 4
count in
cells /µl
421 391 276 61
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? 38% of the patients had CD4 count between 350-500 cells/ µl.
? The CD4 count range was between 200-349 cells/ µl in 36% of the
patients.
? 14% of the patients had CD4 count between 50-199 cells/ µl.
? 10% of the patients had a CD4 count more than 500 cells/µl.
? Only 2% of the patients had CD4 count <50 cells/µl.
    The mean CD4 counts were found to be 421, 391, 276, 61 cells/µl in the
WHO stages I, II, III and IV respectively. The CD4 count ranged between 38-
921 cells/µl. The mean CD4 count was found to be 341.4 cells/ µl. There is no
statistically significant difference between the mean CD4 count between the
stages I and II (p value = 0.6013). There is a significant difference between the
mean CD4 count between stages I and III (p value = 0.0062). There is a
significant difference between the CD4 counts in stages 1and 4(p value =
0.0014). A statistically significant difference (p value = 0.0244) is found
between the CD4 counts of stages II and IV. There is a statistically significant
difference  in  the  CD4  counts  of  stages  II  and  IV  (p  value  <0.0001).  On
analyzing the mean CD4 counts of stages III and IV, a statistically significant
difference is found (p value= 0.0139).
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RANGE OF VIRAL LOAD COPIES PER ml IN
HIV INFECTED PATIENTS
Viral load
ranges
WHO staging- no of patients
Total no of
patients
Percentage of
patientsStage
I
Stage
II
Stage
III
Stage
IV
<1.5×10 3 0 3 5 0 8 16%
1.5-7 ×10 3 1 6 3 0 10 20%
7-20 ×10 3 4 1 6 0 11 22%
20-55 ×10 3 8 0 4 1 13 26%
>55 ×10 3 6 0 0 2 8 16%
Mean viral
load
95458 2694 11897 125924
MEAN VIRAL LOAD IN DIFFERENT
STAGES
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? 26% of the patients had viral load between 20-55×103 /ml.
? 22% of the patients had viral load ranging between 7-20 ×103/ml.
? The viral load range was between 1.5-7×103/ml in 20% of the patients.
? 16% of the patients had a viral load   > 55 ×103 /ml.
? Viral load of less than 1.5×103/ml was seen in 16% of the patients.
 The viral load ranged between 1×102 to 4.58×106 copies/ml. The mean
viral load was found to be 4.8×104 copies/ml. There is a statistically
significant difference in the viral load between stage 1 and 2 (p value
=0.0412).  A significant difference is observed in the viral load between
stage 1 and 3 (p value = 0.0135). There is no significant difference in the
viral loads between stages 1 and 4 (p value = 0.7117). A significant
difference in the viral load is observed between stages 2 and 3 (p value =
0.0302). Stages 3 and 4 showed a significant difference in viral load (p
value <0.0001).
43
OPPORTUNISTIC INFECTIONS IN DIFFERENT
CD4 COUNT CATEGORIES
OPPORTUNISTIC
INFECTIONS
CD 4 count- no of patients Total
<50 50-
200
200-
350
350-
500
>500
Pulmonary
Tuberculosis
0 4 3 2 0 9
Oral candidiasis 0 5 5 4 0 14
Infective diarrhoea 0 2 0 2 0 4
Recurrent URI 0 0 1 1 0 2
Herpes zoster 0 2 0 1 0 3
Oesophageal
candidiasis
1 1 0 0 0 2
Extra pulmonary
Tuberculosis
1 0 0 0 0 1
? The most common opportunistic infection was found to be oral
candidiasis, seen in 28% of the patients.
?  This  was  followed  by  pulmonary  tuberculosis  seen  in  18%  of  the
patients.
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TUBERCULOSIS IN DIFFERENT CD4
CATEGORIES
CD4 count No of patients with
tuberculosis
Percentage
>500 0 0%
350-500 2 4%
200-350 3 6%
50-199 4 8%
<50 1 2%
? A total number of 10 patients were found to have tuberculosis.
?  None of the tuberculosis patients had a CD4 count > 500 cells/µl.
? A maximum of 8 patients had CD4 count < 350 cells/ µl.
?  Of the 10 patients, one of them had extrapulmonary tuberculosis (CNS
tuberculosis). This patient had a CD4 count < 50 cells/µl.
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CORRELATION BETWEEN VIRAL LOAD AND
CD4 COUNT
Correlation coefficient = -0.3800 (P= 0.0065)
There was a significant correlation between increasing HIV RNA levels and
decreasing CD4 counts.
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AGE DISTRIBUTION IN THE STUDY
Age group
(in years)
No of
patients
Percentage
Birth -12 years      0      0%
13-20 years      1      2%
20-50 years     43     86%
>50 years      6     12%
? 86% (43) of the patients belong to the 20-50 years age group.
? 12% (6) of the patients were above 50 years of age.
?  2% (1) of the patients were in the 13- 20 years age group
AGE DISTRIBUTION IN THE STUDY
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SEX DISTRIBUTION IN THE STUDY
Males –29    (58%)
Females –20   (40%)
Transgender -1 (2%)
58%
40%
2%
Males
Females
Transgender
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RISK FACTORS FOR HIV ACQUISITION
Risk factor No of patients Percentage
Heterosexual high risk behaviour          45        90%
Heterosexual with Injection drug abuse           2         4%
Homosexual           1         2%
Mother to child transmission           1         2%
Bisexual           1         2%
? 45(90%) of the patients showed heterosexual high risk behavior alone.
?  1 (2%) of the patients showed homosexual behavior.
?  Heterosexual high risk behavior with Injection drug abuse was found in 2
(4%) of the patients.
? Mother to child transmission was seen in 1 (2%) patient.
? One (2%) of the patients showed Bisexual high risk behavior.
RISK FACTORS FOR HIV ACQUISITION
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HBV STATUS
    No of positives: 7(14%)
    No of negatives: 43(86%)
 43 of the patients were negative for HBV. 7 of them were positive for HBV.
14%
86%
HBV status
POSITIVE
NEGATIVE
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CLINICAL PRESENTATION
Clinical presentation
(symptoms and signs)
        No of patients             Percentage
Asymptomatic 17 34%
Weight loss 7 14%
Diarrhoea 4 8%
Fever 12 24%
Asthenia 2 4%
Cough 10 20%
Dermatoses 28 56%
? The most common clinical presentation was various dermatoses
(56%).
? 34% of the patients were asymptomatic.
?  Fever was seen in 24% and cough in 20% of the patients.
? 14% of the patients presented with weight loss.
?  Diarrhoea was seen in 8% of the patients.
?  4% of the patients had asthenia as the presenting symptom.
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 SEXUALLY TRANSMITTED INFECTIONS
Sexually transmitted
infections No of patients
Syphilis (VDRL Positivity) 4
Genital herpes 1
Perianal Wart 1
Vulvovaginal candidiasis 4
Trichomoniasis 2
Bacterial vaginosis 1
? In this study 4 patients had Syphilis (VDRL Reactive) out of which 3
were males and 1 was a female.
? Vulvovaginal candidiasis is the most common STI co-infection among
females.
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DERMATOLOGICAL MANIFESTATIONS
Oral candidiasis 14 28%
Pruritic papular
dermatoses 4 8%
Extensive
dermatophytoses 2 4%
Herpes zoster 3 6%
Folliculitis 4 8%
Angular cheilitis 3 6%
Tinea capitis 1 2%
Scrofuloderma 1 2%
Seborrheic dermatitis 2 4%
Exfoliative dermatitis 1 2%
Aphthous ulcer 1 2%
? Oral candidiasis was found to be the most common mucocutaneous
manifestation (28%) .
?  The other manifestations observed were folliculitis (8%), papular
dermatoses (8%), herpes zoster (6%), angular cheilitis(6%),
seborrheic dermatitis(2%), extensive dermatophytoses (4%), tinea
capitis (2%), scrofuloderma(2%), exfoliative dermatitis (2%),
aphthous ulcer (2%).
DERMATOPHYTOSIS ANGULAR CHEILITIS
PRURITIC PAPULAR ERUPTIONS
SCROFULODERMA HERPES ZOSTER
EXFOLIATIVE DERMATITIS
SEBORRHEIC DERMATITIS
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SUMMARY OF THE RESULTS
Most common age group affected 20-50 Yrs
Male: female ratio 29:20
Most common risk factor for HIV
transmission
 Heterosexual high risk behavior
Mean CD4 count 341cells/µL
CD4 count range 38-921 Cells/µL
Mean viral load 4.8 × 104 copies/ml
Viral load range 1× 102 to 458×106 copies /ml.
Correlation between CD4 count and
viral load
Correlation coefficient is -0.38
(negative correlation )
Discussion
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DISCUSSION
           This study was carried out to determine the clinical status,
immunological  status  (CD4  count)  and  virological  status  at  the  time  of
presentation. In most of the supporting studies it was found that the progression
of HIV infection  to AIDS is determined by the basal viral load of the patients at
the time of presentation. Thus in the present era of advanced molecular
techniques , it becomes imperative to assess the virological status of the
patients.
       In this study a total of 50 treatment naïve HIV positive patients were
randomly selected and assessed for clinical, immunological and virological
status. The opportunistic infections and their relation to the CD4 count and viral
load was analysed.
? In  this   study  the  most  common  risk  factor  was  found  to  be
heterosexual high risk behavior in concordance with other studies.
? Injection drug abuse was observed in 2 patients belonging to low
socioeconomic status and educational status.
? In this  study, the most common clinical presentation were found to
be various dermatoses. Thus it is important to screen for HIV
infection among the patients with dermatological conditions such
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as pruritic papular eruption, oral candidiasis, widespread
furunculosis , widespread dermatophytoses.
? Among the dermatological manifestations observed oral
candidiasis was the most common, seen in 28% of the patients. It is
observed that in various studies oropharyngeal candidiasis is the
most common opportunistic infection occurring in upto 90% of the
patients at some point of time during the course of HIV infection. It
precedes most other opportunistic infections and it may be a sign of
transition to AIDS. 57,58
? One of the patients in this study had severe cutaneous drug reaction
in the form of exfoliative dermatitis associated with fever, jaundice
and elevated liver enzymes . From various studies it was found that
the incidence of cutaneous drug reactions from a variety of drugs is
high in HIV infection. These drug eruptions tend to be even more
severe in HIV infected than in HIV uninfected patients.59
? In this study 19 patients who belonged to stage 1 disease were
asymptomatic. Most of the patients were diagnosed to have HIV
infection by partner screening. This stresses the importance of
partner screening in the patients.
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? In this 2 of the patients were asymptomatic for more than 8 years
while their partners have progressed to AIDS and died. This can be
explained by the fact that they may be long term non progressors.
Their CD4 counts were 339, 351 and viral load was found to be
1,371,400.
? In this study highest number of patients were in stage 1 (19) and
least  in  stage  4  (3).  Thus  it  may  be  inferred  that  the  number  of
patients diagnosed in the earlier stage of the disease has
considerably increased because of increased awareness in the
community about the disease and effective screening system
available.
? The most common opportunistic infection in our study was oral
candidiasis followed by tuberculosis. Tuberculosis was observed in
patients with a CD4 count <500 cells / µl. Of the 10 patients who
presented with tuberculosis, only 2 of the patients had a CD4 count
between 350- 500 cells /µl. The remaining 8 patients had a CD4
count < 350 cells/ µl. 1 patient who had a CD4 count < 50 cells /µl
presented with extrapulmonary tuberculosis. This is in concordance
with a study in which tuberculosis was found to be most common
in the CD4 count range of 200 -500 cells/µl.60
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? 3 of the patients in stage 4 had a CD4 count below 100. All  the 3
of them had AIDS associated wasting syndrome, 2 of them had
oesophageal  candidiasis  and  one  of  them  presented  with
extrapulmonary tuberculosis. Thus there is a strong negative
correlation between CD4 count and incidence of opportunistic
infections.
? In this study baseline mean CD4 count was found to be 341
signifying  severe immunosuppression. The range of CD4 count
was  found  to  be  38  –  921  cells  /  µl.  A  similar  study  done  by
Gautam et al in New Delhi showed a mean CD4 count of 140 cells/
µl.61
? In this study there was a significant difference in the CD4 counts
 (p < 0.005) among patients belonging to the different stages. The
CD4 count decreased with increasing stage of the disease. Natural
history studies and clinical trials have shown that the CD4 count is
an independent risk factor for progression to AIDS. It estimates the
immunological status of the patient and it is an excellent marker of
immediate risk for opportunistic infection.62
? It is also found that 90% of the patients had a CD4 count below
500 cells/ µl and infections occur with higher frequency in these
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patients. 8 patients had CD4 count < 200 cells/µl which is a severe
state of immunosuppression when a host of opportunistic infections
occur.
? In  this  study  viral  copies  determined  by  Real  time  PCR  ranged
from 1×102 copies to 4.58× 10 6 copies / ml.  The mean viral load
was found to be 4.8×104 copies/ml. The plasma HIV RNA levels
differed between different clinical stages. Mean viral load in stage
2 was found to be 2×103 copies/ml  and  stage  3  was  found  to  be
11×103copies/ml  in  contrast   to  stage  4  where  it  was  found  to  be
1.2× 105copies/ml. There is  a significant difference in the viral
load between these stages
(p< 0.001).
? WHO stage 4 patients (n=3), had circulating viral levels
comparable to those observed during the peak viral replication in
WHO stage 1
( asymptomatic patients ). In stage 4 it was found to be 1.2×105
copies/ml and in stage 1 it was found to be 9.5×104 copies/ml. (p
value is 0.7117, not significant).
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? High viral load in stage 1 can be explained by the fact that early
part of stage 1 (1-2 years of infection) is the time during which the
viral replication is maximum before the cell mediated immunity
mounts an immune response and controls the viral replication.
After the initial viral load peak there will be a steep decline in viral
load within 2 years after the HIV infection to reach the steady state
level. Many of our patients might have  been diagnosed in the
earliest part of HIV infection ( before reaching Viral set point)
? High viral load in stage 4 can be explained by the fact that there is
a complete loss of immunological control over viral replication and
there is also a very low CD4 count at this stage.
? There was also significant  correlation between increasing RT PCR
determined HIV RNA levels and absolute CD4 counts .
(correlation coefficient = - 0.3800) ( p= 0.0065).
      All these observations are in agreement with the study done by Piatak et al 63
Conclusion
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CONCLUSION
? In this study the most common risk factor elicited was heterosexual high
risk behavior. Injection drug abuse and mother to child transmission was
also observed.
? The most common presentation was various dermatoses followed by
upper respiratory tract infections and cachexia.
? Oral candidiasis was the most common mucocutaneous manifestation
observed.
? There was a strong correlation between increased frequency of
opportunistic infections and low CD4 count.
? Tuberculosis was found to be more common when CD4 count is less than
350 cells /µl
? There was strong  correlation between the worsening stage of the disease
and decreasing CD4 count.
? Stage 1 HIV infection had very high viral load may be because most of
the patients were in their earliest part of the Stage 1 disease. A relatively
high CD 4 count was observed in these patients.
? Stage 4 showed a very high viral load and a very low CD 4 count which
is well correlated with the pathogenesis of the disease.
? Stage 2 and 3 had significantly low viral load and a declining CD 4 count.
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Proforma
PROFORMA
                                                          1.  PATIENT PROFILE
Patient ID No:
Date of registration:
Patient referred from: STD clinic / ART centre:
Name of the patient:
Age:
Sex:
Patients phone no:
Address :( Urban /Rural):
Education status:
Occupation:
If Patient diagnosed HIV positive in any other centre : YES/ NO
If yes where:
Purpose for referral:
                                                                        2. HISTORY
Chief complaints:
History of presenting complaint:
                                                                3. MEDICAL HISTORY
HBV carrier: Yes                            No                            Unknown
HCV Carrier:Yes                            No                            Unknown
Other STI: Yes /No (specify if yes)
Diabetes                                      Hypertension                      cardiovascular disease
Present or past history of tuberculosis:
Current medications:
4.PERSONAL HISTORY
Risk factor for HIV
                            Heterosexual
                            MSM
                            Injection drug use
                            Blood transfusion
                            Mother to child
                            Probable unsafe  injection
                            Unknown
Habit of alcohol use:
Habit of smoking:
Use of condoms :
5.FAMILY HISTORY
Marital status:
Single          married           divorced
Widow /widower
Family members
Partner/children
Age/sex HIV
status
ART
Y/N
6. CLINICAL EXAMINATION:
GENERAL EXAMINATION:     PULSE    :                      BP :
CARDIOVASCULAR SYSTEM:
RESPIRATORY SYSTEM:
ABDOMEN:
CNS EXAMINATION:
GENITAL EXAMINATION:
DERMATOLOGICAL EXAMINATION:
7. TYPE OF TUBERCULOSIS AND TREATMENT TAKEN:
DISEASE CLASS
Pulmonary
Extra pulmonary
Past history
TB  Regimen
Category I
Category   II
Category   III
8.
dd/mm/yy WHO clinical
       stage
Weight
    kg
Height
     cm
CD 4
count
Viral
load
9.OTHER INVESTIGATIONS:
Investigations Date Values
Hb
TLC
DLC
ESR
PLT
Serum creatinine
Blood urea
Blood sugar
SGOT
SGPT
VDRL
HBs Ag
Chest X Ray
Master Chart
Patients
code Age Sex
Mari-
tal
status
Years
since
diagnosis
Clinical diagnosis at the time
of presentation
Tuber
-culosis
status
HBV
status
Y/N
Risk
fators
Partner/
children
HIV
status
STI'S Dermatoses WHOstaging
CD 4
cell
count
Viral
load
P001 23 TG S 1 Yr Asymptomatic No No homo NIL I 419 12388
P002 27 F MR 1 month Loss of weight,Oral candidiasis No No hetero H+ C- VVC  Oral candidiasis III 55 8542
P003 46 F MR 2 Yrs Asymptomatic No No hetero H+   C- NIL I 327 23129
P004 30 F MR 1 Yr malaise, anaemia No No hetero H+   C- NIL I 324 80252
P005 35 M MR 2 yrs PUO,Oral candidiasis No No hetero W- C- Syphilis Oral candidiasis, PPD II 302 3359
P006 56 F MR 3 yrs Asymptomatic No No hetero H+   C- NIL I 705 23346
P007 35 F W 2 Yrs Asymptomatic No No hetero H+ NIL I 368 67816
P008 43 M MR 6 months CVA,Oral candidiasis No No hetero UK oral candidiasis II 438 1973
P009 30 F W 3 yrs PUO, URI,Oral candidiasis No No hetero H+ VVC oral candidiasis II 488 2200
P010 43 M MR 2 months
Tuberculosis, oral
candidiasis,herpes zoster Yes No hetero W- C-
oral candidiasis,
herpes zoster III 131 31203
P011 39 M MR 8 months Asymptomatic No No hetero W+ C- Syphilis NIL I 390 23002
P012 35 M MR 1 yr
hepatitis B,
Tuberculosis,anaemia Yes Yes hetero W+ C+ NIL III 68 9243
P013 23 F W 6 yrs Asymptomatic No No hetero H+ C- NIL I 921 41344
P014 27 M S 3 Yrs PUO, Diarrhoea,Oral candidiasis No No hetero Oral candidiasis III 447 2334
P015 33 F MR 7 yrs Asymptomatic No No hetero H + C+ VVC NIL I 447 77231
P016 27 F MR 8 yrs Asymptomatic No No hetero H + NIL I 519 3463
P017 32 M MR 1 yr pruritic papules No No hetero,iv W- C- PPD II 505 212
P018 34 M MR 1mth Asymptomatic No No hetero,iv W- NIL I 226 372033
P019 30 M MR 2yrs Tuberculosis,Oral candidiasis Yes No hetero W- Oral candidiasis III 386 1276
P20 29 F MR 3 yrs Asymptomatic No No hetero H+C+ NIL I 368 458492
P021 38 M MR 7 mths
fever,hepatitis B,Oral
candidiasis No Yes hetero W-C- oral candidiasis, PPD III 211 29842
P022 47 M S 6 yrs folliculitis No Yes hetero folliculitis II 356 3459
P023 30 M MR 2 yrs tuberculosis,anaemia Yes No hetero W+ herpes zoster III 443 1370
P024 54 M MR 8 days extensive dermatophytosis No No hetero W+
angular cheilitis,
dermatophytosis III 268 1263
Patients
code Age Sex
Mari-
tal
status
Years
since
diagnosis
Clinical diagnosis at the time
of presentation
Tuber
-culosis
status
HBV
status
Y/N
Risk
fators
Partner/
children
HIV
status
STI'S Dermatoses WHOstaging
CD 4
cell
count
Viral
load
P025 14 M S 3 mths tinea capitis,fever No No MTCT M+ pustular tinea capitis III 364 16711
P026 31 F MR 3 yrs Asymptomatic No No hetero H+C+ VVC NIL I 308 30034
P027 51 M MR 7yrs herpes zoster,candidiasis No No hetero W+C- Oral candidiasis III 339 3331
P028 49 F MR 3yrs itching all over the body No No hetero H+ NIL I 459 18990
P029 34 M MR new
herpes genitalis,latent
syphilis,tuberculosis ,weight loss Yes No hetero Uk Syphilis
herpes genitalis,
scrofuloderma III 333 4457
P030 48 M MR new
oesophageal candidiasis,weight
loss,anaemia,extra pulmonary
tuberculosis Yes Yes hetero UK NIL IV 38 197432
P031 31 M MR new sycosis barbae No No hetero W- sycosis barbae II 412 1183
P032 30 F MR new Asymptomatic No No hetero H+ NIL I 503 12542
P033 48 M MR 3mths fever,oral candidiasis Yes Yes hetero W+ oral candidiasis III 301 11932
P034 40 M MR new
recurrent fever,seborrheic
dermatitis,angular
cheilitis,tuberculosis Yes No hetero UK
angular cheilitis,
seborrheic dermatitis III 254 100
P035 38 M MR new
recurrent
fever,tuberculosis,chronic
diarrhoea,Oral
candidiasis,herpes zoster Yes No hetero W+
oral candidiasis,herpes
zoster III 184 7112
P036 41 F W new Asymptomatic No No hetero H+C- TV NIL I 223 142971
P037 38 M MR new
wasting syndrome,prolonged
fever,oral aphthae,prolonged
diarrhoea,Oral candidiasis No No hetero W+C-
Oral Aphthae, Oral
candidiasis IV 92 49025
P038 30 M S new
Asthenia,Furunculosis,dermatop
hytoses No No hetero
Furunculosis,
dermatophytosis II 342 1114
P039 42 M MR new
Wasting syndrome,oesophageal
candidiasis No No hetero W+
angular cheilitis,oral
candidiasis,pallor IV 53 131315
P040 36 F MR new Asymptomatic No No hetero H+ Syphilis NIL I 309 43671
P041 44 M MR new perianal wart No Yes bisexual W+ Perianal wart II 220 7114
Patients
code Age Sex
Mari-
tal
status
Years
since
diagnosis
Clinical diagnosis at the time
of presentation
Tuber
-culosis
status
HBV
status
Y/N
Risk
fators
Partner/
children
HIV
status
STI'S Dermatoses WHOstaging
CD 4
cell
count
Viral
load
P042 44 F W new
Prolonged fever,tuberculosis
exfoliative dermatitis Yes No hetero H+ TV
Generalised pruritus,
exfoliative dermatitis III 65 29022
P043 40 M MR new
Tuberculosis,papular pruritic
eruption,Fever Yes No hetero W+C-uk PPD III 296 40021
P044 55 F MR new
Prolonged diarrhoea,prolonged
fever,Weight loss No No hetero H+ BV
diffuse pigmentation of
skin III 493 1459
P045 55 F MR new Weight loss No No hetero H+C- Generalised pruritus II 492 3981
P046 23 F MR new Asymptomatic No No hetero H+C- NIL I 466 12899
P047 46 F MR 2 Yrs Asymptomatic No No hetero H+   C- NIL I 327 38862
P048 39 M MR 8 months Asymptomatic No No hetero W+ C- NIL I 390 331241
P049 47 M S 6 yrs folliculitis No Yes hetero folliculitis II 356 2345
P050 51 M MR 7yrs herpes zoster,candidiasis No No hetero W+C- Oral candidiasis III 339 3331
KEY TO MASTER CHART
1. M : Male
2. F : Female
3. TG : Transgender
4. Hetero: Heterosexual
5. Homo: Homosexual
6. S:Single
7. MR: Married
8. Yrs: Years
9. Mths: Months
10.  PUO:  Pyrexia of unknown origin
11. URI: Upper respiratory tract infection
12. CVA: Cerebro vascular accident
13.W+    : Wife is tested positive for HIV infection
14. H+ : Husband is tested positive for HIV infection
15. C+ : Child is tested positive for HIV infection
16. W- : Wife is tested negative for HIV infection
17. H- : Husband is tested negative for HIV infection
18. C- : Child is tested negative for HIV infection.
19. IV : Intravenous drug abuse
20. PPD: Pruritic papular dermatoses
21. W: Widow
22. UK- Unknown
23. M+ : Mother is tested positive for HIV infection
24. MTCT : mother to child transmission
25. STI’S : Sexually transmitted infections
26. VVC: Vulvovaginal candidiasis
27. BV: Bacterial vaginosis
28. TV: Trichomonas vaginalis vaginitis
PATIENT CONSENT FORM
Title of the study : _“A Real-Time PCR based study on HIV viral load  and its
correlation with the clinical and immunological status of the HIV positive patients”
Name of the participant:    ………………………………………………………………
Name of the Primary Investigator: Dr.G.Rajesh Kumar
Name of the institution: Institute of Venereology
Documentation of the informed consent:
I …………………………………………………….have read the information in this form
I was free to ask any questions and they have been answered
To be included as a participant in the above study.
1. I have read and under stood this consent form and the information provided.
2. I have had the consent document explained to me.
3. I have been explained about the nature of the study.
4. The rights and responsibilities have been explained to me by the investigator.
5. I am aware of the fact that I can opt out of the study at any time
6. I hereby give permission to the investigators to release the information obtained as a result of
participation in this study to the sponsors, regulatory authorities,Govt.Agencies and IEC. I
understand that they are publicly presented.
7. My identity will be kept confidential if those data are publicly presented.
8. By signing this consent form I attest that the information given in this document and the HIV
consent form have been clearly explained to me .
Date:                                                                                                     Signature of the patient
